




ELSEVIER

Prostaglandins & other Lipid Mediators 61 (2000) 425

PROSTAGLANDINS
& other
LIPID MEDIATORS

Author Index

- Abe, F., 395
Ataumi, G., 23
Bahouth, S.W., 343
Cantini, C., 117
Capdevila, J.H., 271
Castellani, S., 117
Cherubini, V., 351
Chilton, F.h., 23
Chu, S., 45
Cirino, M., 145
Clay, C.E., 23
Colville-Nash, P.R., 33
Cristofari, C., 117
Denis, D., 145
Dhillon, H., 165
Di Serio, C., 117
Dohi, T., 385
Dussault, I., 1
Edelstein, C., 45
Fain, J.N., 343
Falcioni, G., 351
Falck, J.R., 271, 321
Fiorini, R., 351
Fonteh, A.N., 23
Forman, B.M., 1
Ghosh, S., 45
Gilroy, D.W., 33
Greene, M.E., 45
Hessler, E., 15
High, K.P., 23
Hishinuma, T., 135, 173, 395, 157157
Hitchingham, L., 15
Ishizawa, F., 157157
Junger, H., 335
Kantar, A., 351
Kitayama, S., 385
Kuhn, H., 255
Kulmacz, R.J., 231
Kummerow, F.A., 183
Kurihara, H., 385
La Cava, G., 117
Lai, P.-S., 321
Lee, f., 45
Leffler, C.W., 343
Littarru, G.P., 351
MacDonald, J., 15
Mahfouz, M.M., 183
Masotti, G., 117
Maxey, K.M., 15
McCarville, M.A., 45
McClay, E.F., 75
Metters, K.M., 145
Mizugaki, M., 135, 157, 173, 395
Mizuno, N., 385
Morita, K., 385
Namen, A.M., 23
Nantel, F., 145
Newport, J.A., 45
Northey, A., 145
Nurai, Y., 173
Oberyszyn, T.M., 367
Omata, K., 395
Parrett, M.L., 367
Pitts, J., 45
Rice, A.M., 343
Rivkees, S.A., 343
Ross, M.S., 367
Satoh, J., 173
Shibata, K., 385
Shinohara, H., 385
Sorkin, L.S., 335
Sugiyama, S.I.M., 395
Suzuki, N., 173, 395
Tiano, L., 351
Tong, H., 165
Toyota, T., 173
Tsai, A.-L., 231
Ungar, A., 117
Vallotti, B., 117
Wang, X.S., 45
Wilgus, T.A., 367
Wong, P.Y.-J., 321
Wood, C.E., 165
Yamazaki, T., 135, 157157
Yoshino, H., 385





ELSEVIER

Prostaglandins & other Lipid Mediators 61 (2000) 427–428

**PROSTAGLANDINS
& other
LIPID MEDIATORS**

Subject Index

- Aging kidney, 117
Arachidonic acid, 271
Asthma, 395
Atherosclerosis, 255
Autacoid, 117
Biologic responses, 23
Bovine aorta, 157
Camptothecin analogues, 75
Cancer cells, 23
Ca²⁺, 385
Catechins, 157
Cerebral ischemia, 165
CPA, 343
Cutaneous inflammation, 367
Cyclooxygenase, 15
Cyclooxygenase-2, 343
Cyclooxygenase inhibitor, 367
Cyclopentenone, 33
Cyclopentenone prostaglandins, 75
Cytochrome P450, 271
Determination, 173
Dexamethasone, 343
Diabetes mellitus, 135, 173
Diabetes type I, 351
Diabetic platelets, 351
14(R), 15(S)-EET epoxyeicosatrienoic acid(14,15-EET) binding, 321
Eicosanoids, 255, 335
Endogenous eicosanoid mediator, 15
Endothelial cells, 157
Epigallocatechin gallate, 157
Epoxygenase, 271
Fatty acids, 1, 157
Fetus, 165
Gc/SIM, 135
Gene regulation, 45
Gene transcription, 23
Goblet cell, 145
GPM, 321
Hematopoietic, 45
12-HETE, 385
Hormone, 45
Human platelets, 183
Human skin cancer, 367
Hydroxylase, 271
Inflammation, 255, 335
In situ hybridization, 145
Intestine, 145
Isolated systolic hypertension, 117
Isoproterenol, 343
Iso-prostaglandin, 335
Leukotrienes E₄ (or LTE₄), 395
Ligands, 23
Lipoxygenase, 271
Lysophosphatidylcholine, 183
Malignant cells, 75
Membrane modification, 351
Microdetermination, 395
Molecular enzymology, 255
Monooxygenase, 271
mRNA, 165
Neutrophils, 385
NS-398, 343
Nuclear receptors, 1, 45
Oxidative response, 351
Oxidized low-density lipoprotein, 183
Peroxisome proliferator, 1, 23, 33, 45
Platelet-activating factor, 385
PPAR, 135
PPAR γ , 23
Pro-inflammatory enzyme, 33
Prostaglandin, 1, 33, 145, 173
Epi-Prostaglandin, 335
Prostaglandin E 2, 343
8-Epi-Prostaglandin F₂, 173
Prostaglandin F-type, 15
Prostaglandin HS-1, 165, 231
Prostaglandin HS-2, 165, 231
 Δ^{12} -Prostaglandin J₂, 75
15-deoxy- $\Delta^{12,14}$ Prostaglandin J₂, 15, 23

Prostaglandin J series, 23
Receptors, 145
RT-PCR, 165
Stomach, 145

Structural biology, 255
Thiazolidinediones, 23
Thromboxane, 135, 183,
395

Troglitazone, 135
Tyrosyl radicals, 231
Vascular permeability,
335